Get the Stockscreener App
5.17
1.78%
0.10
Clene Inc stock is traded at $5.17, with a volume of 63,879.
It is up +1.78% in the last 24 hours and down -17.44% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$5.07
Open:
$5.09
24h Volume:
63,879
Relative Volume:
0.36
Market Cap:
$60.78M
Revenue:
$442.00K
Net Income/Loss:
$-30.46M
P/E Ratio:
-1.1592
EPS:
-4.46
Net Cash Flow:
$-27.47M
1W Performance:
+9.09%
1M Performance:
-17.44%
6M Performance:
+41.37%
1Y Performance:
+14.16%
1-Day Range:
$4.93
$5.25
1-Week Range:
$4.74
$5.43
52-Week Range:
$2.2801
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
5.16 | 59.72M | 442.00K | -30.46M | -27.47M | -4.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.11 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.03 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.84 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
355.66 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.45 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Top Nanotechnology Stocks To Follow NowJanuary 26th - MarketBeat
Breakout Watch: Will Clene Inc benefit from AI trendsPortfolio Gains Summary & Capital Protection Trade Alerts - baoquankhu1.vn
Promising Nanotechnology Stocks To Follow TodayJanuary 25th - MarketBeat
Aug Breakouts: Should I buy Tile Shop Holdings Inc stock now2025 Trading Volume Trends & AI Based Trade Execution Alerts - baoquankhu1.vn
Nanotechnology Stocks To Watch TodayJanuary 24th - MarketBeat
Chidozie Ugwumba Sells 12,665 Shares of Clene (NASDAQ:CLNN) Stock - MarketBeat
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 5,556 Shares of Stock - MarketBeat
Technical Analysis: How do insiders feel about Clene Inc Equity WarrantQuarterly Earnings Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Promising Nanotechnology Stocks To Watch NowJanuary 23rd - MarketBeat
Clene Inc. (NASDAQ:CLNN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2 - Yahoo Finance
Nanotechnology Stocks To Watch NowJanuary 22nd - MarketBeat
Chidozie Ugwumba Sells 12,119 Shares of Clene (NASDAQ:CLNN) Stock - MarketBeat
Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 7,923 Shares - MarketBeat
Chidozie Ugwumba Sells 12,432 Shares of Clene (NASDAQ:CLNN) Stock - MarketBeat
Clene Inc. ten percent owner sells $161k in shares By Investing.com - Investing.com Australia
Clene Inc. ten percent owner sells $161k in shares - Investing.com
CLNN: FDA to review ALS therapy data this quarter; NDA filing and commercialization targeted for 2025 - TradingView
Should I hold or sell Regency Centers Corporation nowQuarterly Trade Report & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Top Nanotechnology Stocks To Follow TodayJanuary 8th - MarketBeat
Insider Buy: What is the PEG ratio of Clene Inc2025 Trading Recap & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream - Investing News Network
Best Nanotechnology Stocks To Add to Your WatchlistJanuary 19th - MarketBeat
Promising Nanotechnology Stocks To Add to Your WatchlistJanuary 18th - MarketBeat
Top Nanotechnology Stocks To Add to Your WatchlistJanuary 4th - MarketBeat
Nanotechnology Stocks Worth WatchingJanuary 17th - MarketBeat
Growth Value: Will PG E Corporation Preferred Security benefit from rising consumer demandSell Signal & Intraday High Probability Alerts - baoquankhu1.vn
Clene Inc. ten percent owner sells $292,184 in shares By Investing.com - Investing.com Australia
Trading Action: Is Clene Inc exposed to currency risksEarnings Growth Report & High Conviction Investment Ideas - baoquankhu1.vn
Shorts Report: Will CLNN stock recover after earningsMarket Movement Recap & Weekly Return Optimization Plans - baoquankhu1.vn
Aug Technicals: Is Clene Inc Equity Warrant stock a smart retirement pickWeekly Risk Summary & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Best Nanotechnology Stocks Worth WatchingJanuary 16th - MarketBeat
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 19,621 Shares of Stock - MarketBeat
Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 26,105 Shares - MarketBeat
Clene Inc. ten percent owner sells $292,184 in shares - Investing.com
Clene to Present at the Emerging Growth Conference - Investing News Network
Best Nanotechnology Stocks To Follow TodayJanuary 15th - MarketBeat
Clene, FDA to discuss survival data and approval path for CNM-Au8 - ALS News Today
Winners Losers: Is Clene Inc a top pick in the sectorGap Up & Long-Term Growth Stock Strategies - baoquankhu1.vn
Risks Report: Is Clene Inc Equity Warrant stock positioned well for digital economyWeekly Profit Summary & AI Forecasted Entry/Exit Points - Bộ Nội Vụ
Clene (NASDAQ:CLNN) Director David Matlin Purchases 33,333 Shares of Stock - MarketBeat
Insider Buying: David Matlin Acquires Shares of Clene Inc (CLNN) - GuruFocus
Clene Announces Multi-Tranche Financing to Extend Cash Runway - TipRanks
Clene Signs Multiple Financing Agreements - TradingView
Forecast Cut: Is Clene Inc. stock dividend yield sustainableQuarterly Profit Report & High Accuracy Investment Entry Signals - Bộ Nội Vụ
Promising Nanotechnology Stocks To Follow NowJanuary 13th - MarketBeat
FDA grants Clene in-person meeting to discuss ALS drug biomarker data - Investing.com Nigeria
Published on: 2026-01-13 07:04:12 - Улправда
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $19,457.55 in Stock - MarketBeat
Clene Inc. ten percent owner sells $256k in shares - Investing.com
Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 32,705 Shares of Stock - MarketBeat
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ugwumba Chidozie | 10% Owner |
Jan 23 '26 |
Sale |
5.27 |
5,556 |
29,280 |
599,603 |
| Ugwumba Chidozie | 10% Owner |
Jan 21 '26 |
Sale |
5.05 |
12,119 |
61,201 |
617,824 |
| Ugwumba Chidozie | 10% Owner |
Jan 20 '26 |
Sale |
4.80 |
12,432 |
59,674 |
629,943 |
| Ugwumba Chidozie | 10% Owner |
Jan 16 '26 |
Sale |
5.13 |
7,923 |
40,645 |
642,375 |
| Ugwumba Chidozie | 10% Owner |
Jan 13 '26 |
Sale |
4.89 |
26,105 |
127,653 |
682,482 |
| Ugwumba Chidozie | 10% Owner |
Jan 14 '26 |
Sale |
5.12 |
19,621 |
100,460 |
662,861 |
| Ugwumba Chidozie | 10% Owner |
Jan 15 '26 |
Sale |
5.10 |
12,563 |
64,071 |
650,298 |
| MATLIN DAVID J | Director |
Jan 13 '26 |
Buy |
6.50 |
33,333 |
216,664 |
477,824 |
| Ugwumba Chidozie | 10% Owner |
Jan 12 '26 |
Sale |
5.50 |
32,705 |
179,878 |
708,587 |
| Ugwumba Chidozie | 10% Owner |
Jan 09 '26 |
Sale |
6.27 |
9,075 |
56,900 |
741,292 |
1.96%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):